4:11 PM ET
8-K
M&A Deal
Fulcrum Therapeutics Signs $7M M&A Deal with Slate Medicines, Inc.
Fulcrum Therapeutics entered into an agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for $7.0 million in cash. The sale is a strategic update to its pending merger with Slate Medicines, as the proceeds will be credited to Fulcrum's net cash and are expected to increase the cash dividend declared in connection with the merger.
- Value
- $7M
- Counterparty
- Slate Medicines, Inc.